The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels

August 19, 2013 updated by: Guangzhou University of Traditional Chinese Medicine
To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after acute cerebral infarction,test is made by random double-blind controlled.patients with acute cerebral infarction were divided randomly into erigeron injection+aspirin group,aspirin group,and health people. The main indexes are the serum level of VEGF, MMP-9 and EPC.The review is made by the reference to NIHSS and so on. So, Erigeron Injection have the function of promoting angiogenesis in multiple targets through this test.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

OBJECTIVE:

To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after acute cerebral infarction.

METHOD:

40 patients with acute cerebral infarction(in accordance with the inclusion criteria) were divided randomly into erigeron injection+aspirin group,aspirin group,and 20 health people. Erigeron injection+aspirin group and aspirin group drew peripheral blood on the prior treatment,the posttreatment 1th, 3th and 7th day,and tested the level of VEGF, MMP-9 and EPC.Tested the health people one time.

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Yefeng Cai, master
  • Phone Number: 34530 (08620)81887233
  • Email: caiyefeng@126.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • patients aged no younger than 18yrs
  • attack within 72 hours
  • NIHSS score in the 2-25 points
  • Ischemic Stroke occurred for the first time, or with a history of stroke disease but without sequelae
  • Signed the informed consents

Exclusion Criteria:

  • patients aged younger than 18yrs
  • Patients with tumor, coronary heart disease, valvular heart disease, psoriasis, rheumatism, hematologic diseases, infertility, varieties of acute inflammation
  • Patients with severe cognitive impairment
  • Refused to cooperate or been unable to cooperation for neurological disorders
  • Cerebral hemorrhage or hemorrhagic cerebral infarction
  • Unstable vital signs dued to massive cerebral infarction
  • Patients with serious heart, liver and renal insufficiency

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Erigeron Injection
Erigeron Injection, 30ml,qd,i.v., for 7 days
Drug: Erigeron Injection
Erigeron Injection, 30ml, iv, qd, for 7days
Placebo Comparator: placebo
normal saline, 500ml,i.v.,qd, for 7 days
Drug: placebo
normal saline, 500ml,i.v.,qd, for 7 days
Other Names:
  • normal saline, 500ml,i.v.,qd, for 7 days
No Intervention: health volunteers
health volunteers, no drug to be given.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
the serum level of VEGF,MMP-9 and EPC
Time Frame: 0-7days
0-7days

Secondary Outcome Measures

Outcome Measure
Time Frame
National Institute of Health of stroke scale
Time Frame: 0-7days
0-7days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Guangzhou University of Traditional Chinese Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2013

Primary Completion (Anticipated)

August 1, 2013

Study Completion (Anticipated)

March 1, 2014

Study Registration Dates

First Submitted

August 19, 2013

First Submitted That Met QC Criteria

August 19, 2013

First Posted (Estimate)

August 21, 2013

Study Record Updates

Last Update Posted (Estimate)

August 21, 2013

Last Update Submitted That Met QC Criteria

August 19, 2013

Last Verified

August 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1201/01/006284

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebral Infarction

Clinical Trials on Erigeron Injection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe